Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "Tecfidera"

ArticleNew data proves Tecfidera's effectiveness in MS, says Biogen14-09-2016
Pharma Letter

kate dawson from biogen tecfidera continues to show real world...

[embedded content] It has been a few years now since Tecfidera was approved by the US Food and Drug Administration. In that time there has bee continued research which has shown positive results for patients. Kate Dawson, MD, from Biogen ... HCPLive, 1 week ago
[x]  

20 images for Tecfidera

Pharma Letter, 1 week ago
pharmaphorum, 1 week ago
Nasdaq, 1 week ago
FiercePharma, 2 months ago
Bidness Etc, 3 months ago
Motley Fool, 5 months ago
European Pharmaceutical Review, 5 months ago
Finchannel.com, 5 months ago
Nasdaq, 5 months ago
Nasdaq, 5 months ago

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Revision: 8, Authorised

This is a summary of the European public assessment report (EPAR) for Tecfidera. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on ...
 European Medicines Agency1 month ago

Opinion/decision on a Paediatric investigation plan (PIP): Tecfidera, Dimethyl fumarate, Therapeutic area: Neurology

| 30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom . Tel. +44 (0)20 3660 6000 . Fax +44
 European Medicines Agency2 months ago
Nasdaq

BRIEF-Biogen CEO to step down; sees FY rev of about $11.2-$11.4 bln

July 21 Biogen Inc Sees 2016 Gaap And Non * George a. Scangos, ph.d., to step down as CEO * Biogen inc says Q2 Tecfidera revenue of $987 million versus. $883.3 million in the same quarter last year * Sees 2016 non-gaap diluted eps is ...
 Reuters UK2 months ago Biogen''s Alzheimer''s Therapy Granted FDA Fast-Track Status  Nasdaq3 weeks ago Biogen's Alzheimer's Therapy Granted FDA Fast-Track Status  Pharmaceutical Tech.com3 weeks ago Biogen CEO Scangos to step down, raising questions about the Big Biotech's future  FiercePharma2 months ago
[x]  

How Does Tecfidera Work?

A study by scientists at the Scripps Research Institute has helped to demystify the molecular workings of the multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate [DMF], Biogen). The drug is the most widely prescribed pill-based therapy for MS, ...
 PT Community1 day ago
Alpha Galileo

The Scripps Research Institute Study Illuminates How Mystery MS Drug Works

Powerful New Research Tool Reveals How Tecfidera® Blocks T-Cell Activation LA JOLLA, CA—September 21, 2016—A study by scientists at The Scripps Research Institute (TSRI) has helped to de-mystify the molecular workings of the multiple sclerosis ...
 BioSpace2 days ago Study illuminates how mystery MS drug works  Science Daily2 days ago TSRI scientists shed light on molecular workings of MS drug  News-Medical.Net3 days ago TSRI Study Illuminates How Mystery MS Drug Works  Infrosoft3 days ago
[x]  

Tecfidera® real-world studies affirm sustained efficacy and safety profile

:22 PM Data presented, from both real-world and clinical settings, demonstrate that dimethyl fumarate delivers consistent1and sustained efficacy2among patients with relapsing-remitting multiple sclerosis (RRMS),and adds to its well-characterised ...
 HospitalHealthcare.com3 days ago TECFIDERA® (DIMETHYL FUMARATE) REAL-WORLD STUDIES AFFIRM SUSTAINED EFFICACY AND DEMONSTRATE 9-YEAR SAFETY PROFILE  PharmiWeb1 week ago
pharmaphorum

Biogen aims real-world data at Tecfidera's patient drop-out problem

Biogen's multiple sclerosis drug Tecfidera has a problem: Arelatively high number of patients start the drug, only to stop taking it later. But now, the company hastrotted out some real-world data it thinks can help turn that problem around. The ...
 FiercePharma5 days ago Biogen takes on Tecfidera adherence issues  pharmaphorum1 week ago

VideoBiogen's Ralph Kern talks about Tecfidera, Zinbryta and being an MS pioneer16-09-2016

Ralph Kern, senior vice president, medical affairs for US biotech major Biogen (Nasdaq: BIIB), talks to The Pharma Letter at the 2016 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) about the company's ...
 Pharma Letter1 week ago
FiercePharma

Biogen's top commercial exec leaves amid Tecfidera sales trouble

When a top biopharma executive abruptly shoves off, what comes next? Questions. Make that departing exec a sales-and-marketing chief, and couple that departure with slowing sales of a key product, and the questions multiply. Tony Kingsley That's ...
 FiercePharma2 months ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Tecfidera
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less